logo
White House sends Dr. Oz to calm Senate nerves

White House sends Dr. Oz to calm Senate nerves

Yahoo7 hours ago

The Senate Republican megabill is ailing. The White House thinks it has a doctor for that.
Dr. Mehmet Oz, the celebrity surgeon best known for dispensing medical advice on television and now a top Trump health official, has emerged as the administration's go-to salesman for the sweeping Medicaid overhaul at the center of the GOP's legislative ambitions.
Oz is increasingly pressing Republicans to back controversial cuts to the health program for low-income Americans, trekking to Capitol Hill several times in recent weeks to push for their support. He's privately counseled Republican senators and governors nervous over the potential fallout for their home states, and publicly promoted the far-reaching changes in a flurry of interviews.
And as the White House and Congress race to meet a self-imposed July 4 deadline to pass the legislation, officials are betting that Oz's medical credentials — and his personal star power — can convince Republicans and their constituents to embrace the legislation despite warnings it will cost millions of people their health care coverage.
"The more he can be out talking to members, and just in general, about the changes we're making and why they're so important and good is very helpful," said Sen. John Hoeven (R-N.D.), who has urged senior White House aides to deploy Oz more frequently in the coming days. "We think we've put together a good product, but there's others that we're still working to get on board."
The megabill push represents the most visible role Oz has taken since joining the administration in April as Medicaid and Medicare chief, where he oversees an agency responsible for more than 160 million Americans' health care despite having little government or policymaking experience.
It's also perhaps the toughest sales job of his career, requiring Oz to sway skeptical Republicans in favor of policies that are projected to eliminate health insurance for 16 million people — many of whom live in red states.
Several Republicans remain wary of provisions that could cut insurance coverage and upend the finances of hospitals in their states. They've bristled at the efforts by Oz and others to downplay the tax-and-spending bill's implications, threatening to withhold their votes over worries it would decimate access to care where it's most needed.
"Our goal here needs to be to protect rural hospitals and make sure that they can keep their doors open," said Sen. Josh Hawley (R-Mo.), one of a handful of holdouts who has expressed reservations about the depth of the Medicaid cuts.
At the same time, a separate GOP faction has demanded deeper cuts to government spending, with some taking their case this week directly to President Donald Trump. And among the public, polls show only a small minority of Americans support the overall bill.
The White House is nevertheless counting on Oz to play a central role in building support for the legislation, calculating that he has both the health care background and the bedside manner to assuage lawmakers' policy concerns.
A cardiothoracic surgeon by training, Oz became a daytime television fixture first as a health expert for The Oprah Winfrey Show before helming his own health and wellness show for more than a decade. A longtime Trump friend who frequently speaks with the president, the 65 year old has also maintained close ties to some Republican senators from his own failed run for office just a few years ago.
On Monday, Oz met with Senate Republican chiefs of staff to push for a decision on a so-called provider tax provision that has proven particularly politically divisive, while also trying to dissuade them from seeking new, deeper Medicaid cuts. The session followed an appearance last week at GOP senators' group lunch to pitch the merits of the bill's health care provisions.
'He's a very big asset in getting us across the finish line,' said a White House official, granted anonymity to discuss internal strategy. 'He has a lot of credibility to go into these lawmaker discussions, to talk to them and hear concerns out and then give the administration's viewpoint."
Within the administration, Oz helped shape the White House's public messaging on Medicaid, at various points blaming "lots of lobbyists" for fueling criticism of the bill, while downplaying its impact on health coverage across a series of television interviews — even amid nonpartisan projections that hundreds of billions of dollars would be cut from the safety net program.
'There is no scenario, not in this bill, not in anywhere I've seen, where we're not spending more money on Medicaid,' Oz said in a recent Newsmax interview.
Those aggressive performances have won praise among Trump officials, who dispatched him at times to help lawmakers and other allies workshop their own talking points. The work has also raised Oz's standing in the White House, where senior aides have been impressed by what two White House officials familiar with the dynamics and granted anonymity to discuss them described as his willingness to be a team player in government after decades as a high-profile celebrity.
"For over a decade, Dr. Oz developed a personal rapport with millions of Americans who tuned into his iconic TV show about health and wellness," White House spokesman Kush Desai said in a statement, adding that as CMS administrator he's "leveraging the immense intellect and telegenic charm he used to build that following to now help President Trump deliver on his mandate of protecting and preserving Medicaid by slashing waste, fraud, and abuse.'
Yet as the megabill hits the home stretch, the persistent divide among Republican lawmakers has also exposed the limits of his salesmanship. Despite overseeing the Medicaid program and facing the task of enacting whatever policy is signed into law, Oz — barely three months into his first government job — has had little direct control over the specifics of the policy negotiations. Those details have instead been coordinated largely between White House domestic policy aides and Republican leaders on the Hill.
Hawley — who briefly raised concerns about Oz during his confirmation process over the surgeon's past support for gender-affirming care — on Tuesday said he hasn't talked with Oz about his Medicaid concerns and saw little value in meeting with him. 'He's not the decisionmaker,' he said. 'The president is.'
That distance has limited his ability to win over skeptics across the health care industry, including hospital groups that have been particularly outspoken in drumming up concerns about the bill's impact on Medicaid.
In one private meeting with hospital representatives earlier this month, Oz listened as they detailed the sprawling financial consequences for providers should Republicans forge ahead with major changes to Medicaid, according to a person in the room. But he had little to offer in response, insisting primarily that the GOP needed to find ways to limit the government's health spending.
"I don't know what he believes," said the person, who was granted anonymity to detail the closed-door discussion. "He's a real bright guy and everything, but he doesn't have control of the policy."
Oz now faces an even trickier situation with the politically delicate provider tax that's divided Republicans on the Hill, jeopardizing the race to the party's July 4 deadline. After Senate lawmakers debuted a deeper funding cut than what Republicans proposed in the House, Oz publicly defended the effort, blasting the existing arrangements between states and hospitals as a form of "legalized money laundering" that the administration needs to remedy, and breaking with Hawley and other GOP skeptics.
"I would disagree that that money goes to rural hospitals," Oz said in a CNN appearance. "The reality is that extra money that's left over goes to hospitals that are better connected, the hospitals with the biggest lobbyists and the best ability to influence what happens in the state capitals."
Yet behind closed doors days later, Oz struck a more measured note, nudging Senate GOP staffers instead to stick to the language laid out by the House.
"He is a really gifted communicator," said Avik Roy, chair of the Foundation for Research on Equal Opportunity and a longtime conservative policy expert. "He may exceed people's expectations. But obviously what matters to some degree is what the policy is. And is the policy something that ordinary people are going to buy as a good policy?"

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Biden aide admits to Congress she directed autopen signatures without knowing who gave final approval
Top Biden aide admits to Congress she directed autopen signatures without knowing who gave final approval

Yahoo

time19 minutes ago

  • Yahoo

Top Biden aide admits to Congress she directed autopen signatures without knowing who gave final approval

A former top aide to President Joe Biden said she was authorized to direct autopen signatures but was unaware of who in the president's inner circle was giving her final clearance, according to a source familiar with the aide's closed-door testimony in front of Congress Tuesday. Neera Tanden, the former director of Biden's Domestic Policy Council, testified for hours Tuesday during an interview in front of the House Oversight Committee, which is investigating the former president's mental acuity and his use of an automatic signature tool that allowed aides to sign pardons, memos and other important documents on Biden's behalf. During Tanden's interview before Congress, which lasted more than five hours, she told lawmakers that, in her role as staff secretary and senior advisor to the former president between 2021 and 2023, she was authorized to direct autopen signatures on behalf of Biden, an Oversight Committee official told Fox News. The system of approval used, according to Tanden's testimony relayed to Fox News, was inherited from previous administrations. Who Is Neera Tanden? The Controversial Dem Operative Who Testified On Biden's Mental Acuity But Tanden, who said she had limited interactions with Biden, described an approval process that left her in the dark about who specifically was giving final approval on the decisions to use the automatic signature tool, sources told Fox News. Tanden testified that to get approval for the use of autopen signatures she would send decision memos to members of Biden's inner circle. However, she added that she was not aware of what actions or approvals took place between the time she sent the decision memo and the time she received it back with the necessary approval. Read On The Fox News App When Tanden was asked whether she ever discussed Biden's health or his fitness to serve as president during her time as a top aide, including during the period of the former president's widely criticized debate performance last summer, Tanden said she did not. Lawmakers laid out a list of names of officials she could have potentially discussed it with, and Tanden said "no" to each name, according to a source familiar with her closed-door testimony. Biden Insists 'I Made The Decisions' As Republicans Investigate White House Autopen Use Tanden did not speak to reporters on the way to the Capitol Tuesday morning. Upon exiting, she expressed her willingness to cooperate with the ongoing investigation. "I just spoke with the House Oversight Committee, Majority and Minority Council. I answered every question, was pleased to discuss my public service and it was a thorough process. And I'm glad I answered everyone's question," Tanden told reporters. When subsequently asked whether there was any effort to hide Biden's condition, Tanden replied, "Absolutely not." In addition to Tanden, Biden's former White House physician, Dr. Kevin O'Connor, will appear for a deposition in front of House Oversight lawmakers after being subpoenaed by Republicans. In addition to O'Connor and Tanden, the Oversight Committee plans to hear from Anthony Bernal, who served as a senior advisor to former first lady Jill Biden; Annie Tomasini, who was Biden's former deputy chief of staff; and Ashley Williams, who was the former deputy director of Oval Office operations under Biden. Oversight Republicans are also seeking interviews with officials who were some of Biden's closest confidants, including former chief of staff Ron Klain and Anita Dunn, a former senior advisor to the president for article source: Top Biden aide admits to Congress she directed autopen signatures without knowing who gave final approval

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Associated Press

time37 minutes ago

  • Associated Press

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

ZUG, Switzerland--(BUSINESS WIRE)--Jun 25, 2025-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4 'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.' BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. 'Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.' PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. 'It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.' DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: . References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol . 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol . 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch . 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio ® U.S. Prescribing Information. Available online . Accessed June 2025 6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR . 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online . Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed June 2025 View source version on CONTACT: For further information: Christian Marcoux, Chief Communications Officer [email protected] +41 76 315 26 50 Richard Harbinson Corporate Communications Director [email protected] +41 76 210 60 62 Céline Buguet Franchises and R&D Communications Director [email protected] +41 76 249 90 87 Emil Ivanov Head of Strategy, Investor Relations, and ESG [email protected] +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director [email protected] +41 21 642 76 43 KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Galderma Copyright Business Wire 2025. PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM

Takeaways from New York City's mayoral primary: Mamdani triggers a political earthquake – and Republicans rejoice too
Takeaways from New York City's mayoral primary: Mamdani triggers a political earthquake – and Republicans rejoice too

CNN

timean hour ago

  • CNN

Takeaways from New York City's mayoral primary: Mamdani triggers a political earthquake – and Republicans rejoice too

Zohran Mamdani delivered a political earthquake Tuesday in New York City's Democratic mayoral primary, riding progressive demands for change in a city facing an affordability crisis to the brink of a stunning victory. Democratic voters rejected a scandal-plagued icon of the party's past, former Gov. Andrew Cuomo. Instead, they backed a 33-year-old democratic socialist who energized young voters and progressives with a campaign that could come to represent the first draft of a new playbook. 'I will fight for a city that works for you, that is affordable for you, that is safe for you,' Mamdani said in his celebratory speech just after midnight. 'We can be free and we can be fed. We can demand what we deserve,' he said. Mamdani's viral, go-anywhere, talk-to-anyone style of campaigning could send shockwaves through the Democratic Party nationally as its leaders and incumbents face calls from frustrated voters for authenticity and aggressiveness. Republicans, meanwhile, moved immediately to elevate Mamdani, seeing an opportunity to campaign against ideas they see as unpopular with swing voters nationally. The formal outcome won't be known until at least July 1, when New York City releases the initial ranked-choice results. But Mamdani held a clear lead Tuesday night, and Cuomo told supporters he had called Mamdani and conceded the primary. 'Tonight is his night. He deserved it. He won,' Cuomo said. Mamdani's upstart campaign had a lot to overcome — Cuomo's universal name recognition, massive financial backing, endorsements from party leaders and unions — and he acted like it. Some of his Democratic rivals portrayed his positions as pie-in-the-sky and impossible to pay for. Mamdani, though, sold his ideas as making life in the city easier to afford, building his campaign around an issue that ranks among the biggest reasons Democrats lost in the 2024 election. He sat for interviews with people that disagreed with him. He engaged in cross-endorsements with rivals, encouraging supporters to rank them highly as well on their ranked-choice ballots. He campaigned aggressively, including walking the length of Manhattan on Friday. 'New Yorkers deserve a Mayor they can see, hear, even yell at. The city is in the streets,' Mamdani said on X. Dan Pfeiffer, a former top aide to President Barack Obama, said on X that Democrats 'have a lot to learn' from Mamdani. 'What's happening in NYC is a blaringly loud message to those in the Dem establishment who still cling to old politics, recite focus-grouped talking points, and are too afraid to say what needs to be said,' he said. Republicans were also thrilled with Mamdani's performance. The House GOP's campaign arm, the National Republican Congressional Committee, issued a press release declaring Mamdani 'the new face' of the Democratic Party. 'Every vulnerable House Democrat will own him, and every Democrat running in a primary will fear him,' NRCC spokesman Mike Marinella said. Mamdani faced attacks from pro-Cuomo forces in the primary over what his opponents described as antisemitic comments, flagging Mamdani's sharp criticism of Israel and his defense of the phrase 'globalize the intifada.' He also ran on progressive positions — including freezing rents, offering free public transit, launching city-run grocery stores and more — that Republicans are certain to use to portray Democrats as extreme, much like they have with previous progressive proposals like the 'Green New Deal.' Those attacks are unlikely to help the GOP in the mayoral race in New York City, where registered Democrats outnumber Republicans almost by about a six-to-one margin. But New York is home to a number of competitive House seats where the GOP could seek to put Democratic nominees on the defensive over Mamdani's positions. It's too soon to sort through everything Mamdani's performance means for the Democratic Party. But it did offer a glimpse at where the party is on some key issues and who within it holds sway with voters. Mamdani, who would become the city's first Muslim mayor if he wins in November, was a vocal critic of Israel's war in Gaza and didn't back down despite being criticized as antisemitic, a charge he repeatedly denied. He defended his views in an interview with CBS' Stephen Colbert in which he also acknowledged the fears Jewish people have faced since Hamas' October 7, 2023, terrorist attack in Israel. 'There's no room for violence in this city, in this country, in this world. And what I have found also, for many New Yorkers, is an ability to navigate disagreement,' he told Colbert. He also demonstrated the influence of progressive New York Rep. Alexandria Ocasio-Cortez, who endorsed Mamdani. Other New York Democratic leaders, including Gov. Kathy Hochul and its two senators, Kirsten Gillibrand and Chuck Schumer, remained publicly neutral. The results similarly laid bare the ineffectiveness of Cuomo's effort — one backed by establishment Democratic forces that blanketed television airwaves but couldn't match the organic groundswell of a state assemblyman who started the race with little public profile. 'Billionaires and lobbyists poured millions against you and our public finance system,' Ocasio-Cortez said of Mamdani on X. 'And you won.' Cuomo had wanted a second act. The 67-year-old scion of one of New York's most prominent political families was forced out of the governor's office in 2021 amid a cloud of scandal — faced with allegations of sexual harassment that he denied and a report that his administration had covered up nursing home deaths during the coronavirus pandemic. The governor and the state's two senators stayed on the sidelines. But Cuomo's campaign was backed by many prominent New York Democrats and groups, including unions and elected officials who had criticized him four years ago but — seeing his lead in the polls — issued devil-we-know statements this year endorsing him. Though ranked-choice ballots need to be counted next week, Cuomo acknowledged the reality he faced on stage Tuesday, telling supporters he had called and congratulated Mamdani. 'Tonight was Assemblyman Mamdani's night, and he put together a great campaign. And he touched young people, and inspired them, and moved them, and got them to come out and vote. And he really ran a highly impactful campaign. I called him, I congratulated him. I applaud him sincerely for his effort, and let's give him a round of applause and thank him for his campaign,' Cuomo said. His former political rivals, meanwhile, gloated over Cuomo's apparent failure. 'Zohran ran a positive campaign talking about affordability. Cuomo ran a very negative, fear-based campaign. That just made a huge difference,' former Mayor Bill de Blasio said on CNN. In overwhelmingly Democratic New York City, a victorious Mamdani would ordinarily become the clear front-runner in November's general election. But he instead faces a competitive race with much different contours. First-term Mayor Eric Adams, who was elected as a Democrat four years ago, is seeking reelection as an independent. Adams' break from the party came as he faced backlash after President Donald Trump's Justice Department dropped its corruption charges against Adams, and Adams has cooperated with federal authorities to enforce Trump's mass deportation efforts. 'What NYC deserves is a mayor who's proud to run on his record – not one who ran from his record, or one who has no record,' Adams posted on X Tuesday night. 'We deserve a mayor who will keep driving down crime, support our police, fight antisemitism, and stand up for working-class New Yorkers.' Republican Curtis Silwa was unopposed in the primary and will be the GOP nominee. And neither Cuomo nor Mamdani had ruled out the possibility of running in November on another party's ballot line if they lost the Democratic contest — Cuomo as the nominee of the newly created Fight and Deliver Party, or Mamdani as the nominee of the Working Families Party.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store